BCTXZNCM

BriaCell Therapeutics Corp.

-20.7% · 90d

$0.12

+0.01 (+9.52%)

News

No News Yet

Press releases and SEC filings for BCTXZ will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.12

Prev Close$0.10

Day Range$0.10 – $0.12

52W Range$0.10 – $0.12

Volume193,495

P/E (TTM)—

EPS—

Dividend Yield—

Beta1.63

About

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

briacell.com

Top Institutional Holders

As of 2025-06-30 · prior 2025-03-31

OSAIC HOLDINGS, INC.$570

1,000 sh● NEW

See all holders →

Quarterly Financials

10/25

Revenue Net Income